Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Esophageal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04819971
What this trial is testing

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Who this might be right for
Stomach Cancer
The First Affiliated Hospital of Zhengzhou University 67
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Testing effectiveness (Phase 2)WithdrawnNCT02274012
What this trial is testing

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Who this might be right for
HER-2 Positive Gastric CancerGastrooesophageal CancerEsophageal Cancer
Columbia University
Testing effectiveness (Phase 2)Study completedNCT01191697
What this trial is testing

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Dana-Farber Cancer Institute 37
Testing effectiveness (Phase 2)Study completedNCT02205047
What this trial is testing

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Malignant Neoplasm of StomachMalignant Neoplasm of Cardio-esophageal Junction of StomachEpidermal Growth Factor Receptor (EGFR) Protein Overexpression
European Organisation for Research and Treatment of Cancer - EORTC 172
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397
What this trial is testing

Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Not applicableStudy completedNCT01220934
What this trial is testing

An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 443
Testing effectiveness (Phase 2)Study completedNCT02004769
What this trial is testing

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsNeoplasms MetastasisERBB2 Gene Amplification
Sun Yat-sen University 67
Large-scale testing (Phase 3)Not Yet RecruitingNCT07818070
What this trial is testing

A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma

Who this might be right for
Gastric CancerEsophagogastric Junction CancerEsophageal Adenocarcinoma
Ono Pharmaceutical Co., Ltd. 600
Not applicableUnknownNCT06550063
What this trial is testing

HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes

Who this might be right for
Esophagus CancerGastric CancerHER2-positive Cancer+1 more
St. James's Hospital, Ireland 2,188
Large-scale testing (Phase 3)UnknownNCT00450203
What this trial is testing

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Who this might be right for
Oesophagogastric Cancer
Professor David Cunningham 1,103
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06374888
What this trial is testing

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Who this might be right for
Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Convalife (Shanghai) Co., Ltd. 28
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07126561
What this trial is testing

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Who this might be right for
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
University of Chicago 43
Testing effectiveness (Phase 2)UnknownNCT03185988
What this trial is testing

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Who this might be right for
Targeted TherapyHER2Biliary Tract Cancer+2 more
Shen Lin 100
Testing effectiveness (Phase 2)Ended earlyNCT01774851
What this trial is testing

MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Who this might be right for
HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction Cancer+1 more
Merrimack Pharmaceuticals 84
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Not applicableLooking for participantsNCT07124000
What this trial is testing

DESTINY-PANTUMOUR04

Who this might be right for
Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more
AstraZeneca 100
Testing effectiveness (Phase 2)Study completedNCT01503983
What this trial is testing

Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

Who this might be right for
Stage IV Gastric Cancer With Metastasis
Fundación para el Progreso de la Oncología en Cantabria 45
Next Page
565